Fate Therapeutics Inc (FATE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
79
About the Report
About the Report
Summary
Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company's pipeline product candidates include cellular immunotherapy pipeline, immuno-oncology candidates, and immuno-regulatory candidates. Its immuno-oncology product candidates include adaptive NK, pluripotent cell-derived cancer immunotherapies, and engineered CAR and TCR T- cell immunotherapies. Its products are derived from pluripotent cells. Fate Therapeutics uses ex vivo cell programming approach to include cell-surface proteins, rapid and supra-physiologic activation or inhibition of therapeutically-relevant genes, and to regulate the therapeutic function. The company's immuno-regulatory cellular therapies promote immune system homeostasis for patients undergoing hematopoietic cell transplantation and immune disorders. Fate Therapeutics is headquartered in San Diego, California, the US.
Fate Therapeutics Inc (FATE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Fate Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Fate Therapeutics Raises USD8 Million in Venture Financing 12
Fate Therapeutics Raises USD 20 Million In Venture financing 13
Fate Therapeutics Raises USD 9.2 Million In Venture financing 14
Partnerships 15
Fate Therapeutics Enters into Agreement with ONO Pharma 15
Fate Therapeutics Enters into Partnership with University of California San Diego 16
Fate Therapeutics Expands Research Agreement with Regents of the University of Minnesota 17
Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 18
Licensing Agreements 19
Fate Therapeutics Enters into License Agreement with Gladstone Institutes 19
Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 20
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22
Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24
Equity Offering 25
Fate Therapeutics Raises USD143.8 Million in Public Offering of Shares 25
Fate Therapeutics Raises USD46 Million in Public Offering of Shares 27
Fate Therapeutics to Raise Funds through Public Offering of Shares 29
Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 30
Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 32
Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 34
Fate Therapeutics Raises USD10.3 Million in Private Placement of Shares 35
Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 36
Fate Therapeutics Completes IPO For USD 46 Million 38
Fate Therapeutics Inc-Key Competitors 39
Fate Therapeutics Inc-Key Employees 40
Fate Therapeutics Inc-Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 01, 2018: Fate Therapeutics reports third quarter 2018 financial results and highlights operational progress 42
Aug 06, 2018: Fate therapeutics announces second quarter 2018 financial results and highlights operational progress 44
May 10, 2018: Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress 46
Mar 05, 2018: Fate Therapeutics Announces Fourth Quarter 2017 Financial Results 48
Nov 01, 2017: Fate Therapeutics Reports Third Quarter 2017 Financial Results 50
Aug 14, 2017: Fate Therapeutics Reports Second Quarter 2017 Financial Results 52
May 15, 2017: Fate Therapeutics Reports First Quarter 2017 Financial Results 54
Mar 16, 2017: Fate Therapeutics Reports Fourth Quarter 2016 Financial Results 56
Corporate Communications 58
Oct 04, 2018: Fate Therapeutics names Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations 58
Sep 14, 2017: Fate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development 59
Product News 60
12/11/2017: Fate Therapeutics Announces Successful Completion of Technology Transfer and Initiation of IND-Enabling Manufacture of FT500 60
12/09/2017: Fate Therapeutics Announces Generation of CAR-targeted, TCR-null CD8aß+ T Cells from Clonal Engineered Master Pluripotent Cell Line for Off-the-Shelf T-cell Immunotherapy 61
05/10/2017: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 in Advanced Solid Tumors 62
03/13/2017: Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy 63
02/23/2018: Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy 64
Clinical Trials 65
Apr 16, 2018: Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program 65
Mar 29, 2018: Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 66
Mar 19, 2018: Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune 67
Feb 20, 2018: Fate Therapeutics Announces First Subject Treated with FATE-NK100 in DIMENSION Study for Advanced Solid Tumors 68
Dec 11, 2017: Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune and Initiation of Phase 2 Stage 70
Dec 08, 2017: Fate Therapeutics Announces First Subject Treated with FATE-NK100 in APOLLO Study for Recurrent Ovarian Cancer 72
Nov 10, 2017: Fate Therapeutics Announces Initial Clinical Data from Ongoing First-in-Human VOYAGE Study of FATE-NK100 for Relapsed / Refractory Acute Myelogenous Leukemia at SITC 2017 Annual Meeting 73
Nov 01, 2017: Fate Therapeutics Will Present Clinical Data From PROTECT Study of ProTmune at 2017 ASH Annual Meeting 75
Sep 18, 2017: Fate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune for Prevention of Acute Graft-versus-Host Disease 76
Aug 08, 2017: Fate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for FATE-NK100 77
Jan 05, 2017: Fate Therapeutics Announces First Patient Treated in ProTmune PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
List of Figure
List of Figures
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fate Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fate Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Fate Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Fate Therapeutics Raises USD8 Million in Venture Financing 12
Fate Therapeutics Raises USD 20 Million In Venture financing 13
Fate Therapeutics Raises USD 9.2 Million In Venture financing 14
Fate Therapeutics Enters into Agreement with ONO Pharma 15
Fate Therapeutics Enters into Partnership with University of California San Diego 16
Fate Therapeutics Expands Research Agreement with Regents of the University of Minnesota 17
Fate Therapeutics Enters into Research Agreement with Boston Children's Hospital 18
Fate Therapeutics Enters into License Agreement with Gladstone Institutes 19
Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 20
Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 22
Fate Therapeutics Enters into Licensing Agreement with Board of Trustees of the Leland Stanford Junior University 24
Fate Therapeutics Raises USD143.8 Million in Public Offering of Shares 25
Fate Therapeutics Raises USD46 Million in Public Offering of Shares 27
Fate Therapeutics to Raise Funds through Public Offering of Shares 29
Fate Therapeutics to Raise USD37.5 Million in Private Placement of Preferred Stock 30
Fate Therapeutics to Raise USD19.3 Million in Private Placement of Shares 32
Fate Therapeutics Plans to Raise up to USD12.4 Million in Public Offering of Shares 34
Fate Therapeutics Raises USD10.3 Million in Private Placement of Shares 35
Fate Therapeutics Raises USD34.5 Million in Public Offering of Shares 36
Fate Therapeutics Completes IPO For USD 46 Million 38
Fate Therapeutics Inc, Key Competitors 39
Fate Therapeutics Inc, Key Employees 40
Fate Therapeutics Inc, Subsidiaries 41
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.